Last reviewed · How we verify
NCT06695429: RENACS
Supplementation With Beetroot Juice to Prevent Contrast Associated Nephropathy During Hospitalization for Acute Coronary Syndrome Without ST Elevation
NA trial testing Beetroot juice in Non ST Segment Elevation Acute Coronary Syndrome in 130 participants. Currently enrolling.
30 September 2026
Quick facts
| Lead sponsor | Hospital General Universitario Santa Lucia |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | prevention |
| Enrollment | 130 |
| Start date | 7 October 2024 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 September 2027 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- Beetroot juice — full drug profile →
Conditions studied
- Non ST Segment Elevation Acute Coronary Syndrome — all drugs for Non ST Segment Elevation Acute Coronary Syndrome →
- Contrast Induced Nephropathy — all drugs for Contrast Induced Nephropathy →
Sponsor
Hospital General Universitario Santa Lucia
Who can join
18 and older, any sex, with Non ST Segment Elevation Acute Coronary Syndrome or Contrast Induced Nephropathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to compare the possible beneficial effect of beetroot juice supplementation versus the usual management during hospitalization to prevent contrast-induced nephropathy after cardiac catheterizations. The study includes patients diagnosed with non-ST elevation acute coronary syndrome with a possible indication for catheterism and high risk of kidney injury related to iodinated contrast. The intervention group will drink 500 mL (2 glasses daily, at breakfast and dinner) of beetroot juice added to the usual diet for 7 days or until hospital discharge and will receive the recommendation to maintain a diet rich in inorganic nitrates. The control group will receive the usual diet and recommendations. In both cases, other therapies will be prescribed to prevent contrast-induced nephropathy (hydration and statins) if there is no contraindication. Our hypothesis is that a compound present in beetroot juice, inorganic nitrates, can prevent the deterioration of kidney function related to contrast due to its vasodilatory effect, in addition to improving the subsequent prognosis of coronary heart disease due to its anti-inflammatory and antiproliferative effects, protector of the endothelium and inhibitor of platelet aggregation. Beetroot juice could also be beneficial in this context due to the antioxidant effect of the betalains it contains.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06695429
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Beetroot juice
Trials testing the same drug.
- NCT06598488 — Beetroot Juice: A Natural Boost for Cardiovascular Health in Postmenopausal Women? · NA · completed
- NCT06286748 — Beetroot Extract Supplementation Associated With an Exercise Protocol for Chronic Kidney Disease Patients · NA · recruiting
- NCT06416228 — Beetroot Juice NO Cold Study · Phase 2 · recruiting
- NCT06227091 — The Effect od Beetroot Juice on Forearm Muscle Strength and Muscle EMG Activity After BloodFlow Restriction · NA · enrolling by invitation
- NCT05624125 — BEETroot Juice to Reverse Functional Impairment in PAD · NA · recruiting
Other recruiting trials for Non ST Segment Elevation Acute Coronary Syndrome
Currently open trials in the same condition.
- NCT06197724 — MCG for Identification of Myocardial Ischemia in Suspected NSTE-ACS Patients · recruiting
- NCT06255678 — Angio-based Final Functional Effect of PCI · recruiting
- NCT05117866 — Acetyl Salicylic Elimination Trial JAPAN: The ASET JAPAN Pilot Study · NA · active not recruiting
Other Hospital General Universitario Santa Lucia trials
Trials by the same sponsor.
- NCT03683875 — Ultrasonography of the Neuromuscular Degeneration Behavior in Amyotrophic Lateral Sclerosis · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06695429 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hospital General Universitario Santa Lucia
- Last refreshed: 18 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06695429.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing